Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asston PharmaceuticalsBOM:544445 -0.59%19 Days Payable is 117.18 as of Mar. 2026, which is 45% below its 10-year median of 212.36. GuruFocus rates BOM:544445 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Asston Pharmaceuticals ranks better than 64.19% on this metric.
The historical rank and industry rank for Asston Pharmaceuticals's Days Payable or its related term are showing as below:
BOM:544445'
s Days Payable Range Over the Past 10 Years
Min: 116.35 Med: 212.36 Max: 548.68
Current: 116.35
During the past 5 years, Asston Pharmaceuticals's highest Days Payable was 548.68. The lowest was 116.35. And the median was 212.36.
BOM:544445's Days Payable is ranked better than 64.19% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs BOM:544445: 116.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Asston Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals (BOM:544445) has a Days Payable of 117.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Asston Pharmaceuticals and its competitors. This is 45% below median its historical median of 212.36. Over the past decade, Asston Pharmaceuticals' Days Payable has ranged from 116.35 to 548.68. According to the industry distribution chart, Asston Pharmaceuticals ranks #332 out of 927 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is Asston Pharmaceuticals' Days Payable too high?
Asston Pharmaceuticals' current Days Payable of 117.18 is 45% below median its 10-year median of 212.36. Over the past 10 years, this metric has ranged from a low of 116.35 to a high of 548.68. The Drug Manufacturers industry median Days Payable is 90.28. Asston Pharmaceuticals' value of 117.18 is 29.8% above this industry median. Based on the distribution chart, Asston Pharmaceuticals ranks #332 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Asston Pharmaceuticals ranks #332 out of 927 companies for Days Payable. This puts Asston Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 90.28. Asston Pharmaceuticals' value of 117.18 is 29.8% above this benchmark. Historically, Asston Pharmaceuticals' own Days Payable has ranged from 116.35 to 548.68 over the past decade. While the company's 10-year median is 212.36 vs. the industry median of 90.28, Asston Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asston Pharmaceuticals's current Days Payable of 117.18 is 29.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Asston Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asston Pharmaceuticals's current Days Payable is 117.18, which is 45% below median its own 10-year median of 212.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Days Payable of 117.18. The current Days Payable is 117.18, which is 45% below median its 10-year median of 212.36 and 29.8% above the Drug Manufacturers industry median of 90.28. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Days Payable is 117.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
